LIU Yu-tao. Bispecific Antibody-Drug Conjugate May Become a Potential Treatment Choice for Patients With Advanced NSCLC[J]. Journal of Evidence-Based Medicine, 2025, 25(1): 31-31. DOI: 10.12019/j.issn.1671-5144.202502018
|
Citation:
|
LIU Yu-tao. Bispecific Antibody-Drug Conjugate May Become a Potential Treatment Choice for Patients With Advanced NSCLC[J]. Journal of Evidence-Based Medicine, 2025, 25(1): 31-31. DOI: 10.12019/j.issn.1671-5144.202502018
|
LIU Yu-tao. Bispecific Antibody-Drug Conjugate May Become a Potential Treatment Choice for Patients With Advanced NSCLC[J]. Journal of Evidence-Based Medicine, 2025, 25(1): 31-31. DOI: 10.12019/j.issn.1671-5144.202502018
|
Citation:
|
LIU Yu-tao. Bispecific Antibody-Drug Conjugate May Become a Potential Treatment Choice for Patients With Advanced NSCLC[J]. Journal of Evidence-Based Medicine, 2025, 25(1): 31-31. DOI: 10.12019/j.issn.1671-5144.202502018
|
DownLoad: